News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Inveresk Research (Incorporating CTBR) (IRGI) Reports Record First Quarter Revenues And Increases 2004 Earnings Guidance

10/19/2005 5:11:12 PM

CARY, N.C., May 4 /PRNewswire-FirstCall/ -- Inveresk Research Group, Inc. today announced results for the first quarter ended March 31, 2004. Net service revenue for the first quarter was $76.7 million, an increase of 33% compared with the first quarter of 2003. Income from operations in the quarter was $12.8 million, or 16.7% of net service revenue, compared with income from operations of $8.6 million for the same period in 2003.

Net income in the first quarter of 2004 was $12.3 million, or $0.31 per share on a diluted basis. This includes a $0.03 positive impact to diluted EPS arising from the recognition of a deferred tax asset on carried-forward tax losses in our US operations, net of share offering expenses and residual restructuring costs for the PharmaResearch acquisition.

"Inveresk continues to benefit from its acquisition strategy in recent years and the diversity of its service offering," said Walter Nimmo, President and Chief Executive Officer of Inveresk Research Group, Inc. "Strong enquiry levels in the North American pre-clinical market in the last three quarters have been converted into new business signings, resulting in increasing revenues and an improved business mix at CTBR, our Montreal-based pre-clinical operations. CTBR recorded excellent results in the first quarter and we expect this to continue for the remainder of the year. At the same time our European pre-clinical operation maintained its strong performance of 2003, with demand for its toxicology services in particular remaining buoyant.

"The Clinical business segment delivered profits in line with expectations in the first quarter. Enquiry levels remain strong in North America and Europe, although seasonal factors and some project delays impacted revenues in the first quarter," added Nimmo.

Favorable Canadian dollar and sterling exchange rate movements positively impacted results in the first quarter, although this was offset partially by a $0.4 million negative mark-to-market valuation adjustment with respect to interest rate hedges.

Net cash from operating activities totaled $11.1 million for the three months ended March 31, 2004, compared with $4.8 million in the corresponding period in 2003. Capital expenditure totaled $5.8 million during the same period ($4.3 million in 2003). At March 31, 2004, the Company had gross financial debt of $56.9 million and cash and cash equivalents of $24.9 million. Net days sales outstanding at March 31, 2004 totaled 21.

For the twelve months ended March 31, 2004, new business signings totaled $350 million, $87 million of which were signed in the first quarter of 2004. At March 31, 2004, backlog amounted to approximately $295 million.

"The general environment for all of our businesses remains robust," added Nimmo. "Our diverse service offering will allow Inveresk to meet or exceed our overall growth and profitability objectives for the full year. In light of these factors and our first quarter results, we are increasing our full- year EPS guidance to between $1.36 and $1.39 on a diluted basis."

Conference Call and Webcast Information

Inveresk Research will host a live conference call and webcast tomorrow, May 5, 2004 at 10:00 a.m. EDT to discuss its first quarter performance. To access the webcast, please visit A replay of the webcast will be available shortly after the call until 5:00 p.m. EDT on Tuesday, May 11, 2004.

Information on Inveresk Research

Inveresk Research is a leading provider of drug development services to companies in the pharmaceutical and biotechnology industries. Through its Pre-clinical and Clinical business segments, the Company offers a broad range of drug development services, including pre-clinical safety and pharmacology evaluation services, laboratory sciences services and clinical development services. Inveresk Research is one of a small number of drug development services companies currently providing a comprehensive range of pre-clinical and clinical development services on a world-wide basis. The Company's client base includes major pharmaceutical companies in North America, Europe and Japan, as well as many biotechnology and specialty pharmaceutical companies. For more information on Inveresk Research, visit our Web site at

Statements contained in this press release that are forward-looking are based on current expectations that are subject to a number of uncertainties and risks, and actual results may differ materially. Factors that might cause such a difference include, but are not limited to, risks associated with: the reduction in research and development activities by pharmaceutical and biotechnology clients, changes in government regulations, the effects of interest rate and foreign exchange rate fluctuations, our ability to attract and retain employees, the loss or delay of contracts due to economic uncertainty or other factors, our ability to efficiently manage backlog, our ability to expand our business through strategic acquisitions, competition within the industry and the potential adverse impact of health care reform. Further information about these risks and uncertainties can be found in the information included in the company's recent filings with the Securities and Exchange Commission, including the company's Registration Statement on Form S-3 and Form 10-K.

Inveresk Research Group, Inc. Condensed Consolidated Statements of Operations ($ in thousands, except per share and share data) (Unaudited) Quarter Quarter Ended Ended March 31, March 31, 2004 2003 Net service revenue $ 76,738 $ 57,684 Direct costs excluding depreciation (39,921) (29,278) 36,817 28,406 Selling, general and administrative expenses: Share offering expenses (306) (658) Other selling, general and administrative expenses (19,853) (16,228) Total selling, general and administrative expenses (20,159) (16,886) Depreciation (3,465) (2,949) Amortization of intangibles (348) -- Income from operations 12,845 8,571 Interest income 101 72 Interest expense (899) (971) Income before income taxes 12,047 7,672 Provision for income taxes 250 (295) Net income $ 12,297 $ 7,377 Earnings per share: Basic $ 0.32 $ 0.20 Diluted $ 0.31 $ 0.20 Number of common shares outstanding: Basic 37,923,816 36,081,610 Diluted 39,160,749 37,366,463 Inveresk Research Group, Inc. Segment Analysis ($ in thousands) (Unaudited) Quarter Quarter Ended Ended March 31, March 31, 2004 2003 Net service revenue: Pre-clinical $ 44,377 $ 36,329 Clinical 32,361 21,355 Total 76,738 57,684 Net service revenue less direct costs excluding depreciation: Pre-clinical 23,213 19,505 Clinical 13,604 8,901 Total 36,817 28,406 Net service revenue less direct costs excluding depreciation, as a percentage of net service revenue: Pre-clinical 52.3 % 53.7 % Clinical 42.0 % 41.7 % Total 48.0 % 49.2 % Income from operations: Pre-clinical 11,744 8,782 Clinical 4,173 2,263 Corporate overhead (3,072) (2,474) Total 12,845 8,571 Income from operations as a percentage of net service revenue: Pre-clinical 26.5 % 24.2 % Clinical 12.9 % 10.6 % Total 16.7 % 14.9 % Inveresk Research Group, Inc. Consolidated Balance Sheet Data ($ in thousands) March 31, 2004 December (Unaudited) 31, 2003 Total current assets $ 119,335 $ 115,011 Total other assets 338,083 334,068 Total current liabilities (110,317) (116,393) Total other liabilities (98,295) (98,511) Total shareholders' equity $ 248,806 $ 234,175 Capital Employed March 31, 2004 December (Unaudited) 31, 2003 Total shareholders' equity $ 248,806 $ 234,175 Current portion of long-term debt 7,634 7,857 Long-term debt 49,220 50,941 Cash and cash equivalents (24,928) (24,579) Total capital employed $ 280,732 $ 268,394

Inveresk Research Group, Inc.

CONTACT: Paul Cowan, Chief Financial Officer of Inveresk Research Group,Inc., +1-919-462-2354,; or Matt Dallas of FinancialDynamics, +1-212-850-5627,, for Inveresk Research Group,Inc.

Read at

comments powered by Disqus